Head-to-head · Cost-Efficiency Index
Invyncible vs Hers
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Invyncible
Cost-first shoppers who want compounded GLP-1 combo programs (with B12/glycine) alongside brand Wegovy/Zepbound on one platform.
Visit InvyncibleHers
Cost-first shoppers who want brand-name FDA-approved GLP-1 access with a mainstream telehealth name.
Visit HersThe verdict
Invyncible takes it, leading the Cost-Efficiency Index 59 to 58. Invyncible (operated by Nationwide Telemedicine, LLC, St. Petersburg, FL) sells four semaglutide combo programs ($149-$270) and four tirzepatide combo programs ($180-$318.75), plus an oral semaglutide capsule program at $255.50, across 46 states and DC. Hers still earns a C — Cost-first shoppers who want brand-name FDA-approved GLP-1 access with a mainstream telehealth name.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Invyncible.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Invyncible | Hers |
|---|---|---|
| Cost-Efficiency Index | 59/100 | 58/100 |
| Semaglutide / mo | $149/mo (0.45 mg dose, compounded with glycine + B12) | $348/mo (brand Wegovy, plus a separate fee) |
| Tirzepatide / mo | $180/mo (2.5 mg weekly, 4-week program, compounded) | $448/mo (brand Zepbound, plus a separate fee) |
| Semaglutide / yr (modeled) | $1,788 | $4,176 |
| Tirzepatide / yr (modeled) | $2,160 | $5,376 |
| Coverage | 46 states plus DC | All 50 states |
| Oral / sublingual | Yes | No |
| Brand-name access | Yes | Yes |
| Rank here | #272 | #279 |
Invyncible
59/100Where the value is
- Publishes real itemized dollar prices for eight separate combo programs plus two brand options directly on the site, no signup required, with the mg vial size named in every dose option
- Sells FDA-approved brand Wegovy ($1,750/mo) and Zepbound ($1,540/mo) alongside compounded options
- Names all six compounding pharmacies with street addresses and phone numbers and lets the patient choose which one fills the prescription
The tradeoffs
- Every listed price is shown as a discount off a much higher struck-through 'list' price, and the page invites further negotiation — reads as permanent anchor pricing
- The entry figure is the smallest vial: plain compounded semaglutide runs $192.50, $262.50 and $350 across its three vial sizes, and the FAQ confirms cost rises with dose
Hers
58/100Where the value is
- Sells only FDA-approved branded medications (Wegovy, Zepbound, Ozempic, Mounjaro) rather than compounded versions
- Multiple formats per drug (pill vs pen/vial), including a newer pill option and microdosing plan
- Large, publicly traded parent (Hims & Hers Health) with an established clinical/support infrastructure
The tradeoffs
- The advertised 'From $X/mo' price is medication-only — a mandatory membership fee ($39 first month, then $149/mo, billed separately) is layered on top and roughly doubles the real steady-state monthly cost
- No compounded, lower-cost semaglutide/tirzepatide option was found on the current site
Regulatory note: the FDA issued a warning letter to Hims & Hers Health, Inc. dba Hers in September 2025. We still list and link to Hers; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.